Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (2154)	10/6/1997 11:55:00 AM
From: David S.	of 6136

I think that 6-9 months from now as more data comes out, we'll find out that what are supposed to be the mutation cascades for HIV in the presence of the PI's are not consistent for an individual drug, such as Viracept or Crix. Wheras the conventional wisdom may state that if your virus becomes resistant to Viracept, your virus will have certain specific mutations & within each individual, we will find variation around that basic theme. Therefore, there will be a range of responses to follow on PI therapy. Although this explanation is logical, and almost obvious, it means that there will continue to be arguements about the effectiveness of follow on therapy after resistance has developed to the initial cocktail.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next